摘要
肝脏是结直肠癌血行转移的主要靶器官,且结直肠癌肝转移是影响结直肠癌患者预后的重要因素。根治性的肝段或肝叶切除是目前治疗肝转移的"金标准",但术后5年生存率仅为37%～44%,且只有10%～20%的患者适合手术治疗。其他非手术治疗方案如局部治疗(射频消融术等)、化疗联合分子靶向药物治疗以及基因治疗等正日益受到关注。
Liver is one of the leading hematogenous metastases in patients with colorectal cancer,and the colorectal liver metastases（CRLM）are the main prognostic factor.Although liver resection is the gold standard of CRLM,the 5-year survival rate ranges from 37% to 44%,and only 10%-20% of patients with CRLM are found resectable.Currently,non-surgical treatment,such as local treatment（radiofrequency ablation）,chemotherapy combined with molecular targeted therapy and gene therapy are arousing more attention.
出处
《医学综述》
2010年第11期1641-1643,共3页
Medical Recapitulate
关键词
结直肠癌
肝转移
手术切除
射频消融
Olorectal cancer
Colorectal liver metastases
Resection
Radio frequency
